Across TCGA pan-cancer cohorts, ZNF521 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF521 data layer compared with 27 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZNF521 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF521 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

HNSC, GBM, and LSCC are the cancer types where ZNF521 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.393	0.885	<.001	40	view →
GBM	OS	Tertile	All	0.580	0.252	.001	13	view →
LSCC	DFS	Tertile	II,III,IV	0.804	1.000	.014	10	view →
PDAC	OS	Tertile	All	0.240	0.568	.016	8	view →
LUAD	DFS	Median	All	1.000	0.521	.015	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ZNF521 tumor-vs-normal RNA expression · all ZNF521 data types